Masitinib Plus Gemcitabine in Pancreatic Cancer

Inclusion Criteria

• •1. Histologically or cytologically confirmed adenocarcinoma of the pancreas, non resectable locally advanced or metastatic stage
• •2. Patient with pain related to the disease, as assessed by the investigator and the patient:
• •* Pain related to the disease as assessed by the investigator is defined as clinical and documented evaluation by the investigator during physical examinations at screening and/or baseline.
• •* Pain, as assessed by the patient is defined as at least one value out of two values \> 20mm on Visual Analogue Scale at screening or baseline. Visual Analogic scale consists in the visual representation of pain amplitude as perceived by the patient. The amplitude is represented by a 100 mm long line having no reference marks. One extremity indicates an absence of pain (0 value) and the other the worst imaginable pain (100 value).
• •OR
• •\- Patient treated with opioid analgesics at a dose ≥ 1 mg/kg/day (morphinic equivalent).
• •3\. Chemotherapy naïve patient for the advanced/metastatic disease